MedDataX Logo

Efficacy of the New Closure Device in Improving Patient Compliance in Treatment of Hypertension With Valsartan+/-Hydrochlorothiazide (HCTZ) at 6 Months

NCT00487123 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL

Last updated 2008-06-17

No results posted yet for this study

Summary

This study will evaluate the efficacy of the reminder device Remind Cap® in improving patients' compliance in the consumption of Valsartan +/- Hydrochlorothiazide (HCTZ) in the treatment of hypertension

Conditions

  • Hypertension

Interventions

DRUG

Valsartan+/- Hydrochlorothiazide

Sponsors & Collaborators

  • Novartis

    lead INDUSTRY

Principal Investigators

  • non IND · Sponsor GmbH

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Primary Completion
2007-09-30
Completion
2007-09-30

Countries

  • Singapore

Study Locations

Related Clinical Trials

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00487123 on ClinicalTrials.gov